Neurocrine Biosciences Inc vs Stryker Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 7× Neurocrine Biosciences Inc's market cap, and Stryker Corporation pays a 1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SYK | |
|---|---|---|
Market Cap | $17.40B | $122.35B |
Sector | Health | Technology |
52-Week High | $180.55 | $403.53 |
52-Week Low | $123.10 | $282.58 |
Enterprise Value | $16.49B | $134.10B |
Dividend Yield | — | 1% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →